Torrent Pharmaceuticals Ltd (IN:TORNTPHARM)
:TORNTPHARM
Want to see IN:TORNTPHARM full AI Analyst Report?
TORNTPHARM Stock Chart & Stats
₹3578.85
-₹79.35(-2.33%)
At close: 4:00 PM EST
₹3578.85
-₹79.35(-2.33%)
Day’s Range― - ―
52-Week Range₹3,101.00 - ₹4,479.70
Previous CloseN/A
Volume167.59K
Average Volume (3M)7.49K
Market Cap
₹1.39T
Enterprise Value₹1.45T
Total Cash (Recent Filing)₹10.33B
Total Debt (Recent Filing)₹28.22B
Price to Earnings (P/E)51.3
Beta0.53
Next Earnings
May 21, 2026EPS Estimate
20.19Next Dividend Ex-DateN/A
Dividend Yield0.84%
Share Statistics
EPS (TTM)19.00
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio3.66
Price to Book (P/B)14.19
Price to Sales (P/S)9.52
P/FCF Ratio54.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)80.56
Revenue Forecast (FY)₹149.99B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained, high free cash flow growth and cash conversion (OCF/Net Income 1.35) provide durable internal funding for R&D, capex, dividends or M&A. Strong cash generation reduces dependence on external financing and supports long‑term strategic investments and balance sheet resilience.
Healthy Balance SheetA 50.6% equity ratio and lower leverage (D/E 0.42) give financial flexibility to weather downturns and fund expansion without stressing liquidity. Coupled with a high ROE, this enables the company to reinvest profitably and pursue strategic opportunities with limited refinancing risk.
Revenue And Margin StrengthConsistent revenue growth with robust gross and very strong EBIT margins point to scalable manufacturing, pricing power in key therapies, and operational efficiency. These durable profitability characteristics support sustainable cash flow and competitive positioning in branded generics.
Bears Say
Lower Net MarginNet margin meaningfully lags gross and EBIT margins, implying taxes, interest or SG&A absorb a significant share of operating profit. Persistently lower net profitability limits retained earnings available for reinvestment and reduces margin buffer against pricing or cost shocks.
Asset UtilizationManagement notes scope to improve asset utilization; if asset turnover is suboptimal, growth may require disproportionate capital deployment. Lower capital efficiency can depress returns on new investments and slow scalable, capital‑efficient expansion over the medium term.
Business Model ExposureReliance on branded generics and exports to regulated/semi‑regulated markets creates structural exposure to price erosion, prescribing shifts and regulatory timing. These persistent competitive and approval risks can pressure margins and growth unless offset by new launches or diversification.
Torrent Pharmaceuticals Ltd News
TORNTPHARM FAQ
What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?
Torrent Pharmaceuticals Ltd lowest stock price was ₹3101.00 and its highest was ₹4479.70 in the past 12 months.
What is Torrent Pharmaceuticals Ltd’s market cap?
Torrent Pharmaceuticals Ltd’s market cap is ₹1.39T.
When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?
Torrent Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 23 days.
How were Torrent Pharmaceuticals Ltd’s earnings last quarter?
Torrent Pharmaceuticals Ltd released its earnings results on Feb 13, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹18.196 by ₹0.804.
Is Torrent Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd pays a Notavailable dividend of ₹6 which represents an annual dividend yield of 0.84%. See more information on Torrent Pharmaceuticals Ltd dividends here
What is Torrent Pharmaceuticals Ltd’s EPS estimate?
Torrent Pharmaceuticals Ltd’s EPS estimate is 20.19.
How many shares outstanding does Torrent Pharmaceuticals Ltd have?
Torrent Pharmaceuticals Ltd has 338,431,850 shares outstanding.
What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?
Torrent Pharmaceuticals Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹18.196. Following the earnings report the stock price went down -0.185%.
Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:TORNTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Technical Analysis
Cipla Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Zydus Lifesciences Limited
―